Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2025-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate pathologic risk features.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00771641

Head and Neck Cancer

COMPLETED PHASE3

Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer

NCT04477759

Head and Neck Neoplasm

COMPLETED PHASE1

Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI

NCT05160714

Head and Neck Cancer

UNKNOWN PHASE1

Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours

NCT06472570

Head and Neck Cancer

RECRUITING NA

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

NCT05674396

Head and Neck Squamous Cell Carcinoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RATIONALE: Postoperative hypofractionated radiation is well established in many malignancies, yielding benefits in compliance, access to care, convenience, and cost savings. In several solid tumor types, short-course high dose-per-fraction (hypofractionated) post-operative radiation has shown excellent tolerability, reduced healthcare costs, improved compliance, and at least equivalent cancer control compared to conventional post-operative radiation (long course, low dose-per-fraction).(1-3) Despite advances in other malignancies, hypofractionated post-operative radiation is not used in previously untreated mucosal HNSCCs, for which an extended course of conventional post-operative radiation (usually 60 Gy in 2 Gy fractions delivered over six weeks) remains the standard. Hypofractionation has been stymied in the post-operative setting for HNSCCs primarily due to concerns of toxicity in treating a large mucosal field and an inability to spare critical structures such as the brain and spinal cord. These concerns were well-founded in the 1970s during the era of 2-dimensional radiotherapy when conventional HNSCC radiotherapy regimens were developed.(4) But because radiotherapy can be delivered far more precisely using intensity modulated radiation therapy (IMRT), it is hypothesized that post-operative radiation for HNSCCs can now be delivered safely in only five fractions delivered over one week.(3, 5, 6)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resectable Head and Neck Squamous Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

This study will use a time-to-event continual reassessment method (TITE-CRM) for assigning subjects to the radiation therapy dosages.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

42 Gray (Gy) Radiation

42 gy of radiation therapy will be administered in 10 fractions.

Group Type EXPERIMENTAL

42 Gy Radiation Therapy

Intervention Type RADIATION

Radiation Therapy: Dose per fraction of 4.2 Gy.

39 Gray (Gy) Radiation

39 gy of radiation therapy will be administered in 8 fractions.

Group Type EXPERIMENTAL

39 Gy Radiation Therapy

Intervention Type RADIATION

Radiation Therapy: Dose per fraction of 4.875 Gy.

32.5 Gray (Gy) Radiation

32.5 gy of radiation therapy will be administered in 5 fractions.

Group Type EXPERIMENTAL

32.5 Gy Radiation Therapy

Intervention Type RADIATION

Radiation Therapy: Dose per fraction of 6.5 Gy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

42 Gy Radiation Therapy

Radiation Therapy: Dose per fraction of 4.2 Gy.

Intervention Type RADIATION

39 Gy Radiation Therapy

Radiation Therapy: Dose per fraction of 4.875 Gy.

Intervention Type RADIATION

32.5 Gy Radiation Therapy

Radiation Therapy: Dose per fraction of 6.5 Gy.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients 18 years or older with gross totally resected (R0 resection) Human papillomavirus (HPV) -negative squamous cell carcinoma of the head and neck (squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, nasal cavity, paranasal sinuses or carcinoma of unknown head/neck primary) who have at least 1 of the following intermediate risk factors for adjuvant radiation:

1. Pathologic Node Positive Disease
2. Perineural Invasion
3. Oral cavity cancer with depth of invasion of at least 5 mm
4. Lymphovascular Space Invasion
5. Pathologic T3 or T4 disease
2. Zubrod performance status 0-2.
3. Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up.
4. Inclusion of Covid-19 positive patients will be based on standard institutional protocol.
5. Female patients must meet one of the following:

* Postmenopausal for at least one year before the screening visit, or
* Surgically sterile (i.e. undergone a hysterectomy or bilateral oophorectomy), or
* If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agree to practice two acceptable methods of contraception (combination methods requires use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 90 days after the last dose of study agent, AND o Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptom-thermal, post ovulation methods\] and withdrawal are not acceptable contraception methods).
6. Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:

* Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR
* Must also adhere to the guidelines of any study-specific pregnancy prevention program, if applicable, OR o Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptom-thermal, post ovulation methods\] and withdrawal are not acceptable methods of contraception.)
7. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria

1. Pathologic evidence of extranodal extension.
2. Pathologic evidence of a final positive margin (R1 resection) or gross residual disease (R2 resection).
3. HPV-positive squamous cell carcinoma.
4. Prior invasive malignancy within the past 3 years (except for non-melanomatous skin cancer, and early stage treated prostate cancer).
5. Life expectancy less than 12 months.
6. Performance status Zubrod ≥ 3.
7. Patients with prior radiation therapy to the head and neck Note: Prior external beam radiotherapy is excluded, but Iodine 131 is allowed.
8. Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer.
9. Body weight ≤ 30 kg.
10. Any of the following severe laboratory abnormalities within 14 days of registration, unless corrected prior to it: Sodium \< 130 mmol/L or \> 155 mmol/L; Potassium \< 3.5 mmol/L or \> 6 mmol/L; Fasting glucose \< 40 mg/dl or \> 400 mg/dl; Serum calcium (ionized or adjusted for albumin) \< 7 mg/dl or \> 12.5 mg/dl; Magnesium \< 0.9 mg/dl or \> 3 mg/dl.
11. Unstable angina and/or congestive heart failure requiring hospitalization within 3 months prior to Step 1 registration.
12. Transmural myocardial infarction within three months prior to Step 1 registration.
13. Medical or psychiatric illness which would compromise the patient's ability to tolerate treatment or limit compliance with study requirements.
14. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for 6 months after radiation, this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding are also excluded.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No